• Citer

Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trial.

par Tosco, Lorenzo;Laenen, Annouschka;Gevaert, Thomas;Salmon, Isabelle ;Decaestecker, Christine ;Davicioni, Elai;Buerki, Christine;Claessens, F;Swinnen, Johan;Goffin, Karolien;Oyen, Raymond;Everaerts, Wouter;Moris, Lisa;De Meerleer, Gert;Haustermans, Karin;Joniau, Steven;P.E.A.R.L. (ProstatE cAncer Research Leuven),
Référence BMC cancer, 18, 1, page (354)
Publication Publié, 2018-04

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Résumé :

Recent retrospective data suggest that neoadjuvant androgen deprivation therapy can improve the prognosis of high-risk prostate cancer (PCa) patients. Novel androgen receptor pathway inhibitors are nowadays available for treatment of metastatic PCa and these compounds are promising for early stage disease. Apalutamide is a pure androgen antagonist with a very high affinity with the androgen receptor. The combination of apalutamide with degarelix, an LHRH antagonist, could increase the efficacy compared to degarelix alone.